Cellectar Biosciences (CLRB) Financials

$2.41

$0.04 (1.69%)

As on 08-Sep-2026 16:00EDT

Market cap

$22 Mln

Revenue (TTM)

$0 Mln

P/E Ratio

--

P/B Ratio

0.8

Div. Yield

0 %

Annual
Quarterly

Income Statement ($ Mln)	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Operating Revenue	--	--	--	--	--	--
Cost of Revenue	-0.01	0.21	0.29	0.19	0.24	0.23
Gross Profit	0.01	-0.21	-0.29	-0.19	-0.24	-0.23
Operating Expenses	23.64	22.77	51.78	38.96	28.81	24.13
Operating Profit (EBIT)	-23.53	-22.98	-51.78	-38.96	-28.81	-24.13
Other Income	--	--	--	--	--	--
Profit before Tax	-22.32	-21.79	-44.52	-42.83	-28.66	-24.12
Provision for Tax	--	--	0.07	-0.06	-0.06	-0.15
Profit after Tax (Net Income)	-22.32	-21.79	-44.58	-42.77	-28.60	-23.97
Minority Interest	--	--	--	--	--	--
Consolidated Profit	--	--	--	--	-28.60	-24.12

Liabilities ($ Mln)	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Shareholder's Funds	29.87	9.92	14.29	-13.78	9.54	33.05
Minority Interest	--	--	--	--	--	--
Non-Current Liabilities	1.53	0.31	1.79	0.49	0.55	0.17
Current Liabilities	5.24	4.75	9.39	25.36	11.50	3.99
Total Liabilities	41.88	14.98	25.47	12.08	21.59	37.20

Assets ($ Mln)	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Non-Current Assets	1.76	0.94	1.22	1.62	1.06	0.63
Current Assets	34.88	14.04	24.25	10.45	20.53	36.57
Total Assets	41.88	14.98	25.47	12.08	21.59	37.20
Total Debt*	1.53	0.41	0.49	0.55	0.60	0.30
Net Current Assets	29.64	9.29	14.86	-2.48	15.00	32.58

Cashflow ($ Mln)	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Cash From Operating Activities	--	-23.12	-47.58	-32.38	-25.22	-22.57
Cash Flow from Investing Activities	--	-0.01	-0.10	-0.86	-0.23	-0.14
Cash from Financing Activities	--	13.03	61.41	22.94	9.61	1.25
Net Cash Inflow / Outflow	--	--	--	--	--	--

Financials Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Adjusted EPS ($)	-4.55	-5.14	-31.89	-66.07	-92.20	-117.67
Cash EPS ($)	--	-5.09	-31.68	-65.82	-91.72	-116.94
Adjusted Book Value ($)	--	2.34	10.23	--	30.74	162.22
Dividend per Share ($)	--	--	--	--	--	--
Cash Flow per Share ($)	--	-5.45	-34.04	-50.01	-81.31	-110.79
Free Cash Flow per Share ($)	--	-5.45	-34.11	-51.35	-82.04	-111.49

Profitability Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
ROCE (%)	--	-173.51	-5,698.33	2,772.93	-131.54	-54.13
ROE (%)	-112.20	-179.99	-17,221.69	2,016.68	-134.34	-54.58
ROA (%)	-72.67	-107.74	-237.45	-254.09	-97.30	-50.01
EBIT Margin (%)	--	--	--	--	--	--
Net Margin (%)	--	--	--	--	--	--
Cash Profit Margin (%)	--	--	--	--	--	--

Growth Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Revenue Growth (%)	--	--	--	--	--	--
EBIT Growth (%)	46.93	51.05	-3.93	-48.65	-19.40	-59.87
Net Profit Growth (%)	23.21	51.12	-4.23	-49.54	-19.32	-58.80
EPS Growth (%)	77.84	0.84	0.52	0.28	0.22	-9.75
Book Value Growth (%)	-47.38	--	--	--	--	--

Valuation Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Price / Earnings	--	-0.57	-0.01	-0.04	-0.02	-0.01
Price / Book Value	0.78	1.26	0.03	-0.13	0.06	0.00
Dividend Yield (%)	--	--	--	--	--	--
EV/EBITDA	-3.25	0.01	0.51	0.17	0.65	1.47
Close Price ($)	2.78	2.95	8.97	83.10	51.30	199.20
High Price ($)	6.52	20.60	133.50	94.50	237.03	894.00
Low Price ($)	2.20	2.45	6.72	39.00	37.50	174.48
Market Cap ($ Cr)	22.40	--	--	--	--	--

Solvency Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Debt to Equity	--	0.04	0.03	-0.04	0.06	0.01
Short term debt to equity ratio	0.00	0.01	0.01	0.00	0.01	0.00
Current Ratio	6.66	2.96	2.58	0.41	1.78	9.16
Quick Ratio	6.66	--	--	--	--	--
Interest Coverage	--	--	--	--	-95.74	-10,565.36

Operating Efficiency Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Debtors to sales (%)	--	--	--	--	--	--
Asset Turnover	--	--	--	--	--	--
Receivable days	--	--	--	--	--	--
Inventory Days	--	--	--	--	--	--
Payable days	--	4,741.82	6,089.52	7,763.52	3,037.54	2,281.81
Cash Conversion Cycle	--	--	--	--	--	--

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.